Abstract
Severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is a newly identified member of Family Coronaviridae. Coronavirus envelope spike protein S is a class I viral fusion protein which is characterized by the existence of two heptad repeat regions (HR1 and HR2) (forming a complex called fusion core). Here we report that by using in vitro bio-engineering techniques, SARS-CoV HR1 and HR2 bind to each other and form a typical 6-helix bundle. The HR2, either as a synthetic peptide or as a GST-fusion polypeptide, is a potent inhibitor of virus entry. The results do show that SARS-CoV follows the general fusion mechanism of class I viruses and this lays the ground for identification of virus fusion/entry inhibitors for this devastating emerging virus.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Circular Dichroism
-
Dose-Response Relationship, Drug
-
Escherichia coli / metabolism
-
Glutathione Transferase / metabolism
-
Membrane Glycoproteins / chemistry*
-
Peptides / chemistry
-
Protein Conformation
-
Protein Structure, Secondary
-
Protein Structure, Tertiary
-
Recombinant Fusion Proteins / chemistry
-
Recombinant Fusion Proteins / metabolism
-
Severe acute respiratory syndrome-related coronavirus / genetics*
-
Spike Glycoprotein, Coronavirus
-
Temperature
-
Viral Core Proteins / chemistry*
-
Viral Envelope Proteins / chemistry*
-
Viral Fusion Proteins / chemistry
-
Viral Proteins / chemistry
Substances
-
Membrane Glycoproteins
-
Peptides
-
Recombinant Fusion Proteins
-
Spike Glycoprotein, Coronavirus
-
Viral Core Proteins
-
Viral Envelope Proteins
-
Viral Fusion Proteins
-
Viral Proteins
-
spike glycoprotein, SARS-CoV
-
Glutathione Transferase